VJVirtual | INVICTUS and INTRIGUE: investigating ripretinib in patients with advanced GIST

Robin Jones, MD, The Royal Marsden Hospital, London, UK, provides an overview of the Phase III INVICTUS (NCT03353753) trial, investigating the switch-control kinase inhibitor, ripretinib, in patients with advanced gastrointestinal stromal tumors (GIST) who had progressed on at least imatinib, sunitinib and regorafenib. The primary endpoint of progression-free survival (PFS) was met, with patients receiving ripretinib achieving a 6.3 month median PFS, versus a 1 month median PFS for patients receiving placebo. The results lead to the FDA approval of ripretinib in the fourth-line setting for the treatment of advanced GIST. The Phase III INTRIGUE (NCT03673501) clinical trial investigated ripretinib versus sunitinib in patients with advanced GIST previously treated with imatinib, demonstrating no significant difference between ripretinib and sunitinib, although ripretnib showed a superior safety profile.